<DOC>
	<DOCNO>NCT00005766</DOCNO>
	<brief_summary>The objective study determine whether creatine slow disease progression subject amyotrophic lateral sclerosis ( ALS ) . ALS progressive uniformly lethal neurodegenerative disorder know cure . Recent genetic biochemical study implicate free radical toxicity , glutamate excitotoxicity mitochondrial dysfunction possible cause familial ALS ( FALS ) sporadic ALS ( SALS ) . It hypothesize ALS may involvement oxidative free radical damage impair mitochondrial energy metabolism could turn lead excitotoxic cell death . Creatine , agent improve mitochondrial function , show neuroprotective animal model ALS Huntington 's disease . This study double-blind , randomize , placebo-controlled trial safety efficacy creatine patient ALS enrol site distribute throughout United States , include Northeast ALS ( NEALS ) sit . The study provide preliminary data safety efficacy creatine ALS . If creatine slow disease progression ALS well tolerate , phase 3 study survival primary outcome measure initiate . 114 eligible subject randomize receive treatment 6 month ( 1 ) active creatine ( 2 ) placebo . After randomization , subject follow prospectively 6 month . The primary outcome measure study change upper extremity motor function 6 month experimental therapy test Tufts Quantitative Neuromuscular Exam . Strength eight arm muscle measure ( bilateral shoulder elbow flexion extension ) . Secondary outcome measure include grip strength , motor unit number estimate ( MUNE ) , ALS functional rating score-revised ( ALSFRS-R ) , rate change well establish biochemical marker oxidative damage DNA ( 8OH2'dG level urine ) , safety tolerability creatine .</brief_summary>
	<brief_title>Clinical Trial Creatine Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>ALS FVC &gt; =50 % Abnormality upper and/or lower extremity motor function Not pregnant Disease duration &lt; 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>ALS</keyword>
</DOC>